{"id":"capecitabine-oxaliplatin-cetuximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine's mechanism of action is based on its conversion to 5-fluorouracil, which is a thymidylate synthase inhibitor. This inhibition disrupts DNA synthesis in cancer cells, ultimately leading to cell death. Oxaliplatin, on the other hand, works by forming platinum-DNA adducts that prevent DNA replication and transcription. Cetuximab's mechanism involves binding to the EGFR, preventing its activation and subsequent signaling pathways that promote cancer cell growth and survival.","oneSentence":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA in cancer cells, thereby inhibiting their replication. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and subsequent signaling pathways that promote cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:53.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Advanced gastric cancer"}]},"trialDetails":[{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT06490913","phase":"PHASE2","title":"Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-11-01","conditions":"Liver Metastases of Colorectal Cancer","enrollment":33},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT05022030","phase":"PHASE2","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-21","conditions":"Colo-rectal Cancer, Capecitabine, Cetuximab","enrollment":150},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05720559","phase":"PHASE2","title":"Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-01","conditions":"Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer","enrollment":100},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT00954876","phase":"PHASE2","title":"Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer","status":"WITHDRAWN","sponsor":"Translational Genomics Research Institute","startDate":"2009-08","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT05544812","phase":"","title":"A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-05-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT05409417","phase":"PHASE2, PHASE3","title":"Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":40},{"nctId":"NCT00321100","phase":"PHASE2","title":"Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2006-04-12","conditions":"Colorectal Neoplasms","enrollment":23},{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314},{"nctId":"NCT00640081","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Cheryl Pugh","startDate":"2007-07","conditions":"Colorectal Cancer","enrollment":169},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT01247337","phase":"PHASE2","title":"Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma","status":"COMPLETED","sponsor":"Dorte Nielsen","startDate":"2011-02-02","conditions":"Cholangiocarcinoma","enrollment":56},{"nctId":"NCT00353457","phase":"PHASE2","title":"Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2006-02","conditions":"Rectal Cancer","enrollment":6},{"nctId":"NCT00444678","phase":"PHASE2","title":"Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2004-06-01","conditions":"Colorectal Cancer, Neoplasm Metastasis","enrollment":36},{"nctId":"NCT00541112","phase":"PHASE2","title":"Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2007-10-29","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT04232748","phase":"","title":"Change in Body Weight During Treatment of Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Tuen Mun Hospital","startDate":"2019-01-01","conditions":"Cancer, Colorectal, Chemotherapy Effect, Weight Loss","enrollment":264},{"nctId":"NCT00398398","phase":"PHASE2","title":"Study of XELOX With Cetuximab in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-11","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT04160416","phase":"PHASE2","title":"mXELOXIRI Combined With Molecular Targeted Drug in mCRC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-07-01","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":48},{"nctId":"NCT00183898","phase":"PHASE2","title":"Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2004-12-28","conditions":"Gastric Cancer, Esophageal Cancer","enrollment":75},{"nctId":"NCT03923036","phase":"","title":"Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-04","conditions":"Colorectal Cancer Metastatic","enrollment":2000},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT00408564","phase":"PHASE2","title":"Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-01","conditions":"Pancreatic Cancer","enrollment":39},{"nctId":"NCT03567629","phase":"PHASE2","title":"Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-05-29","conditions":"mCRC","enrollment":130},{"nctId":"NCT00686166","phase":"PHASE2","title":"S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-02","conditions":"Colorectal Cancer","enrollment":83},{"nctId":"NCT00226941","phase":"PHASE1, PHASE2","title":"A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer","status":"TERMINATED","sponsor":"George Albert Fisher","startDate":"2004-06","conditions":"Rectal Cancer, Colo-rectal Cancer","enrollment":23},{"nctId":"NCT00483405","phase":"PHASE2","title":"Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-10","conditions":"Liver Cancer","enrollment":33},{"nctId":"NCT01042028","phase":"PHASE1, PHASE2","title":"A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer","status":"TERMINATED","sponsor":"Per Pfeiffer","startDate":"2010-01","conditions":"Pancreatic Cancer","enrollment":39},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT01579357","phase":"PHASE2","title":"Pharmacokinetics and Metabolic Activation of Capecitabine","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2012-02","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72},{"nctId":"NCT00795301","phase":"PHASE2","title":"A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2008-07","conditions":"Rectal Cancer","enrollment":74},{"nctId":"NCT00430027","phase":"NA","title":"Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2006-11","conditions":"Esophageal Adenocarcinoma","enrollment":8},{"nctId":"NCT00182715","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2005-03","conditions":"Colorectal Cancer","enrollment":2421},{"nctId":"NCT00290615","phase":"PHASE2","title":"Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Herbert Hurwitz","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT00338039","phase":"PHASE2","title":"Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Pancreatic Cancer","enrollment":69},{"nctId":"NCT00531115","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.","status":"TERMINATED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":28},{"nctId":"NCT00755534","phase":"PHASE2","title":"Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-11","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT00482222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2007-02","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":340},{"nctId":"NCT00478634","phase":"PHASE1","title":"A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-05","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors","enrollment":19},{"nctId":"NCT00227734","phase":"PHASE2","title":"Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2004-06","conditions":"Colorectal Cancer","enrollment":74},{"nctId":"NCT00208546","phase":"PHASE3","title":"Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2005-06","conditions":"Colorectal Cancer","enrollment":750},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72},{"nctId":"NCT01366118","phase":"NA","title":"Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Rectal Cancer","enrollment":16},{"nctId":"NCT00254137","phase":"PHASE2","title":"Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2004-09","conditions":"Metastatic Colorectal Cancer","enrollment":92},{"nctId":"NCT00383695","phase":"PHASE2","title":"Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":164},{"nctId":"NCT00964457","phase":"PHASE2","title":"Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients","status":"UNKNOWN","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2009-08","conditions":"Rectum Cancer","enrollment":60},{"nctId":"NCT00215722","phase":"PHASE2","title":"XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Grupo de Investigacao do Cancro Digestivo","startDate":"2005-07","conditions":"Colorectal Carcinoma","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["xeloda, oxalitin, Erbitux"],"phase":"phase_2","status":"active","brandName":"Capecitabine, Oxaliplatin, Cetuximab","genericName":"Capecitabine, Oxaliplatin, Cetuximab","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA in cancer cells, thereby inhibiting their replication. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and subsequent signaling pathways that promote cancer cell growth. Used for Metastatic colorectal cancer, Advanced gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}